Predictive Oncology (NASDAQ:POAI) Stock Passes Below 200 Day Moving Average of $2.93

Predictive Oncology Inc. (NASDAQ:POAI)’s share price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.93 and traded as low as $1.29. Predictive Oncology shares last traded at $1.34, with a volume of 24,355 shares changing hands.

Predictive Oncology Price Performance

The stock has a market cap of $5.44 million, a P/E ratio of -0.39 and a beta of 1.28. The firm’s 50-day moving average price is $2.52 and its 200-day moving average price is $2.93.

Predictive Oncology (NASDAQ:POAI) last released its quarterly earnings data on Thursday, March 28th. The medical instruments supplier reported ($0.85) earnings per share (EPS) for the quarter. The company had revenue of $0.34 million for the quarter. Predictive Oncology had a negative net margin of 785.62% and a negative return on equity of 104.21%.

Institutional Investors Weigh In On Predictive Oncology

A hedge fund recently bought a new stake in Predictive Oncology stock. Raymond James & Associates purchased a new position in Predictive Oncology Inc. (NASDAQ:POAI) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 118,229 shares of the medical instruments supplier’s stock, valued at approximately $378,000. Raymond James & Associates owned about 2.93% of Predictive Oncology as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 9.04% of the company’s stock.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.